Antivenoms from hyperimmune animal plasma are the only specific pharmaceuticals against snakebites. The improvement of downstream processing strategies is of great interest, not only in terms of purity profile, but also from yield-to-cost perspective and rational use of plasma of animal origin. We report on development of an efficient refinement strategy for F (ab' ) 2-based antivenom preparation. Process design was driven by the imperative to keep the active principle constantly in solution as a precautionary measure to preserve stability of its conformation (precipitation of active principle or its adsorption to chromatographic stationary phase has been completely avoided). IgG was extracted from hyperimmune horse plasma by 2% (V/V) caprylic acid, depleted from traces of precipitating agent and digested by pepsin. Balance between incomplete IgG fraction breakdown, F (ab' ) 2 over-digestion and loss of the active principle' s protective efficacy was achieved by adjusting pepsin to substrate ratio at the value of 4: 300 (w/w), setting pH to 3. 2 and incubation period to 1. 5 h. Final polishing was accomplished by a combination of diafiltration and flow-through chromatography. Developed manufacturing strategy gave 100% pure and aggregate-free F (ab' ) 2 preparation, as shown by size-exclusion HPLC and confirmed by MS/MS. The overall yield of 75% or higher compares favorably to others so far reported. This optimised procedure looks also promising for large-scale production of therapeutic antivenoms, since high yield of the active drug and fulfillment of the regulatory demand considering purity was achieved. The recovery of the active substance was precisely determined in each purification step enabling accurate estimation of the process cost-effectiveness.
Antivenoms prepared from hyperimmune animal plasma, mostly equine or ovine, are the only specific therapeutics for rapid counteracting post-snakebite pathophysiological manifestations. Although there are various well established downstream processing strategies that have been implemented into commercial scale production, optimisation of compact, high yielding and low-cost manufacturing procedures generating safe, efficacious and available immunotherapeutics is still of great interest. Design of the ideal process should be guided by the tendency to refine immunoglobulin G from residual plasma proteins in only a few easy, simple and efficient purification steps, aiming for good recovery of neutralising activity and regulatory acceptable physicochemical characteristics of the product [1]. Quality of the final product depends also on immunisation scheme that should maximally boost humoral response, giving the highest possible titer of anti-venom antibodies. Many of so far developed strategies as the initial step employ salting-out procedure involving ammonium or sodium sulphate [2–6] that is associated with low purity profile of IgGs as well as excessive formation of aggregates [7,8]. Both shortcomings can be prevailed by introducing caprylic acid as an alternative fractionation agent [7,9, 10] which acts on the majority of plasma proteins without affecting IgG fraction by leaving it in solution and, consequently, preserving its conformational and structural stability [11,12]. Refinement principles employing caprylic acid have been successfully implemented into preparations of a whole series of highly efficacious equine or ovine IgG-based antivenoms [13–17]. They have also been proven beneficial for purification of F (ab' ) 2 derivatives [18,19] and monoclonal antibodies [20]. Following IgG extraction some antivenom manufacturers perform enzyme-mediated separation of the Fc portion of IgG, because it is not important for the neutralisation activity, while its removal contributes to reduction of foreign protein quantity in the product intended for use in humans. It has been generally believed that the lack of the Fc fragment disables complement activation or inhibits the formation of immune complexes that are responsible for the onset of delayed hypersensitivity reactions [11,21,22]. However, poor physicochemical features of the product, i. e. turbidity, high content of IgG or contaminating protein aggregates, also exhibit detrimental impact, which was evidenced irrespective of the presence or absence of the Fc fragment [11,12,22]. Thus, its role in adverse reactions still remains unclear. Enzymatic cleavage can be performed either on unfractionated plasma [1,18,23] or isolated IgGs [1] as well as simultaneously with removal of unwanted proteins by caprylic acid precipitation [19]. Both F (ab' ) 2 or Fab antivenoms have been successfully and widely used in snakebite management for decades [1], with the former ones being considered more clinically efficacious due to their slower elimination rate creditable for long lasting action [24]. Another advantage of F (ab’) 2 fragments is associated with their divalent nature giving them ability to form multivalent immunocomplexes with venom antigens, just like whole IgG molecules. Such complexes may be removed by phagocytic cells, eliminating the toxins from relevant tissue locations. This mechanism does not operate in the case of Fab antibodies. The use of Fab fragments is often associated with recrudescence of envenomation signs, although their rapid distribution might represent desirable pharmacokinetic feature when dealing with venom toxins of comparable molecular weight. Ion-exchange chromatography has been introduced into some refinement strategies as well, proving suitable for separation of F (ab' ) 2 fragments from other plasma proteins under conditions preferring antibody adsorption on cation-exchange stationary phase material [18]. Additionally, it has been recognised also as a method of choice for the final polishing where an anion-exchange approach is favourably used [25]. Other chromatography techniques are also applicable, for example, purification of F (ab' ) 2 fragments by means of affinity chromatography exclusively [26]. Our study aimed for integrating the most efficient segments of the existing technological knowledge from the field into a compact, feasible and economically viable purification strategy for preparation of equine plasma-derived antivenom based on F (ab' ) 2 fragments. The main goal was to design an easily scalable sequence of purification steps in which desired IgG molecules or their fragments would be kept in solution throughout, as a precautionary measure against possible degradation/aggregation of the antibodies due to exposition to harsh condition (precipitation, binding to chromatographic support or high salt/low pH mediated elution) [27–30]. At the same time, effort was put into the preservation of highest process yield and fulfillment of the regulatory requirements concerning final product purity and aggregate content. The aim was also to precisely quantify the recovery of the active drug in each process step to enable accurate estimation of the cost-effectiveness of the designed procedure.
Adult mice (strain NIH Ola/Hsd, both sex, 18–20 g) for lethal toxicity neutralisation assay were purchased from the Institute of Immunology Inc. (Croatia). Animal use protocols were established in accordance to Croatian Law on Animal Welfare (2017) which strictly complies with EC Directive (2010/63/EU). Experiments involving animals were approved by the Croatian Ministry of Agriculture, Veterinary and Food Safety Directorate (UP/I-322-01/17-01/75, permission no. 525-10/0255-17-6). The approval is based on the positive oppinion of the National Ethical Commitee (EP 110/2017). During the test period mice were housed in a 12-h light/12-h dark cycle and at a constant temperature of 22 °C. A standard mouse diet (Mucedola srl. , Italy) and water were supplied ad libitum. Animal monitoring for signs of pain, suffering and distress associated with procedure was performed following severity assessment protocol. Crude venom of V. a. ammodytes (Vaa) and two pools of Vaa-specific hyperimmune horse plasma (HHP) were provided by the Institute of Immunology Inc. Caprylic acid, o-phenylenediamine dihydrochloride (OPD), iodoacetamide (IAA), dithiothreitol (DTT), bovine serum albumin (BSA), Tween 20, thimerosal, 2- (N-morpholino) ethanesulphonic acid (MES) monohydrate and Tris base were from Sigma-Aldrich, USA. Pepsin (from porcine gastric mucosa, 0. 7 Ph. Eur. U/mg) was from Merck, Germany. Goat anti-horse F (ab' ) 2 IgG conjugated with horseradish peroxidase (HRP) was from antibodies-online, Germany. All other chemicals used for preparation of buffers and solutions were from Kemika, Croatia. Purification of IgG using protein A based affinity chromatography was performed by applying 12 mL of 2-fold diluted HHP per run on MabSelect Xtra columns (V = 2 × 1 mL, GE Healthcare, USA) with 20 mM Tris/HCl running buffer, pH 7. 4, at a flow rate of 2 mL min-1. The bound antibodies were eluted with 20 mM citric acid, pH 2. 3, diafiltrated into PBS, pH 7. 0, and formulated with 0. 3 M glycine. A highly purified IgG sample (eIgG) was used as standard in ELISA assay and as model substrate for preliminary optimisation of pepsin digestion. HHP was incubated at 56 °C for 1 h. After centrifugation at 3,200 × g for 40 min and discarding the pellet, caprylic acid was added to 0. 5 mL of supernatant in a dropwise manner so that final concentrations ranging from 1 to 9% (V/V) in 2-fold diluted reaction mixtures (V = 1 mL) were achieved. Precipitation was performed by vigorous stirring (750 rpm) at 23 °C for 1 h in thermomixer (Eppendorf, Germany), followed by sample centrifugation (2,800 × g, 45 min). IgG-enriched supernatant was collected and filtered through a cellulose acetate filter with a pore size of 5 μm (Sartorius, Germany). Minimal caprylic acid concentration giving the highest IgG purity and preserving yield, as preliminary determined, was chosen as optimal for the precipitation. Preliminary optimisation of pepsin digestion was done using a model IgG substrate—highly pure IgG sample (eIgG) isolated from HHP by protein A based affinity chromatography. Generally, substrate aliquots (2 mg mL-1) were pH adjusted using 0. 4 M HCl and tempered according to planned experiments. Pepsin solution (5 mg mL-1) in 0. 15 M NaCl (saline) was added at different enzyme to IgG ratios (as specified in" Results" section) while gently mixing (350 rpm). The final volume of reaction mixture, prepared in saline, was 1 mL. Digestion was terminated at timed intervals with a 0. 4 M NaOH solution until slightly acidic to neutral pH was achieved. Initially, preliminary screening of four factors—pepsin to IgG ratio (1: 300 or 10: 300, w/w), duration of incubation (45,60 or 90 min), pH of the reaction mixture (3. 2 or 3. 5), and temperature (20,37 or 56 °C), was performed according to a general factorial experimental plan that consisted of a total number of 40 runs, four of which were assessed in duplicates. Since it was not possible to execute all runs simultaneously, their order was randomised to avoid systemic errors. We used a regression function model covering linear contribution of each factor, but also non-linear for selected experimental area. In the second experiment duration of enzymatic reaction (X1) and pepsin to IgG ratio (X2), each at two levels (marked with minus (-) for the low and plus (+) for the high level), were further selected to study their impact on the digestion outcome. Their values were 1 or 3 h for X1 and 1: 300 (w/w) or 10: 300 (w/w) for X2. The full factorial design was employed resulting in 4 experimental runs, each performed in triplicate (22 × 3). The main effect of each factor was calculated according to Eq (1), EX=2*ΣY¯+jn−2*ΣY¯‑jn (1) where index X represents factors 1 or 2, n is the total number of experimental runs (4) and Y¯j are F (ab' ) 2 yields obtained at - and + level of each factor. The significance of the given factors was determined by means of ANOVA using Statistica 13. 4 software. Fine-tuning of enzyme quantity with respect to IgG was tested by preparing reaction mixtures with a wide range of discrete pepsin concentrations (from 1: 300 to 10: 300, w/w) that were tested under conditions giving highest yield, according to results from previous experimental sets. All subsequent experiments were performed using real process IgG substrate—IgG fraction from the optimised caprylic acid fractionation step, and examining one variable at a time. The common approach involved acidification to pH 3. 2 and addition of pepsin solution in saline until desired enzyme to IgG ratio in a 1. 5-fold diluted reaction mixture (V = 1 mL) was reached. Incubation was performed at 37 °C for 1. 5 h. When optimal conditions were set, the procedure was scaled up 20-fold. Samples from each experimental set were analysed by SDS-PAGE. The quantity of F (ab' ) 2 fragments from reaction mixtures in which complete IgG cleavage occurred was measured by ELISA (detailed description is given in" ELISA assays for IgG and F (ab' ) 2 content determination" section) and used for yield estimation [%]. For each run mean value and 95% confidence interval (CI) were calculated. IgG-enriched supernatant following caprylic acid precipitation was diafiltrated into water or saline using Vivaspin device (Sartorius, Germany) with a 100 kDa molecular weight cut-off (MWCO) polyethersulfone membrane. F (ab' ) 2 sample, as well as the commercial pepsin preparation employed for its preparation, were dialfiltrated into 20 mM MES buffer + 0. 15 M NaCl, pH 5. 0, on a membrane with a MWCO of 50 kDa. In each diafiltration step the buffer was exchanged by a factor of 8,000 ×. Chromatographic separation of pepsin from F (ab’) 2 fragments was optimised on UNOsphere Q stationary phase (Bio-Rad, USA) in a batch mode with 20 mM MES with or without 0. 15 M NaCl as binding buffer under varying pH conditions (from 4. 0 to 6. 0). Elution was performed with 1 M NaCl in the binding buffer. The starting material was crude F (ab' ) 2—F (ab’) 2 preparation obtained by pepsin digestion of caprylic acid fractionated IgGs (1 mL per 0. 2 mg of stationary phase). The sample (F (ab' ) 2 obtained by pepsin digestion) was loaded (2 mL per run) to the pre-equilibrated CIM QA disk (V = 0. 34 mL; BIA Separations, Slovenia) with 20 mM MES + 0. 15 M NaCl binding buffer, pH 5. 0, at a flow rate of 2 mL min-1 on ÄKTA chromatography system (GE Healthcare, USA). The absorbance was monitored at 280 nm. After collecting the flow-through fraction, the bound components were eluted from the column material with binding buffer containing 1 M NaCl. The enzymatic activity of pepsin was measured spectrophotometrically on Multiskan Spectrum instrument (Thermo Fischer Scientific, USA) using haemoglobin as substrate. Modified Ryle' s protocol was followed [31]. Samples previously diafiltrated into 50 mM KCl, pH 2. 0, using membrane with a MWCO of 10 kDa were prepared in 2-fold serial dilutions in duplicates. Aliquots of 40 μL were incubated with 200 μL of 2. 5% (w/V) bovine haemoglobin solution previously acidified with 0. 3 M HCl (60 μL). After 20 min at 37 °C the reactions were terminated by adding 1 mL of cold 4% (w/V) trichloroacetic acid. Non-degraded substrate was precipitated by centrifugation at 2,750 × g for 10 min and absorbance of the supernatants was measured at 280 nm. Blanks were obtained by omitting samples from reaction mixtures. Purity of the IgG/F (ab' ) 2 sample in each processing step was examined by SDS-PAGE analysis on 4–12% Bis-Tris gel with MES as running buffer under non-reducing conditions in an Xcell SureLock Mini-Cell, according to the manufacturer’s procedure (Invitrogen, USA). Staining was carried out with acidic Coomassie Brilliant Blue (CBB) R250 solution or, alternatively, with silver for detection of pepsin traces. Isoelectric focusing, the first dimension of 2D gel electrophoresis, was performed in a ZOOM IPGRunner Mini-Cell (Invitrogen, USA) using immobilised pH gradient (IPG) strip (7 cm long, linear pH 3–10) (Invitrogen, USA) rehydrated with F (ab' ) 2 sample (350 μg), according to the protocol provided by the manufacturer. The following step voltage protocol was applied: 200 V for 20 min, 450 V for 15 min, 750 V for 15 min and 2,000 V for 180 min. The second dimension utilised SDS-PAGE analysis of the protein focused on IPG strip that was reduced with 20 mM DTT and alkylated with 125 mM IAA prior its loading to 4–12% Bis-Tris gel. Obtained spots served as starting material for mass spectrometry (MS). Excised protein spots obtained by 2D gel electrophoresis of F (ab' ) 2 sample were prepared for MS analysis by in-gel trypsin digestion, as follows. Gel cuts were washed three times in water/acetonitrile (ACN) and once in NH4HCO3/ACN, dried under vacuum, reduced with 10 mM DTT (45 min at 56 °C) and then alkylated with 54 mM IAA (30 min at room temperature (RT) in the dark), both in 100 mM NH4HCO3. Following reduction and alkylation gel pieces were washed with 100 mM NH4HCO3 and ACN, dried and rehydrated in 1–10 μL of porcine trypsin solution (Roche, Germany) (10 ng of trypsin per estimated 1 μg of protein) for 45 min. Digestion was performed in 95% 50 mM NH4HCO3 and 5% ACN (V/V) overnight at 37 °C. Peptide extraction was repeated twice with 1% HCOOH/ACN 1: 1 (V/V) and once more with water/ACN 1: 1 (V/V). Pooled extracts were purified by C18 Zip-Tips (Millipore, USA), dried, dissolved again in 0. 1% trifluoroacetic acid (TFA) /ACN 1: 1 (V/V) and spotted on a stainless steel MALDI target (Bruker, Germany) after mixing with MALDI matrix (α-cyano-4-hydroxycinnamic acid (8 mg mL-1) in 0. 1% TFA/ACN 1: 1 (V/V) ). Measurements were performed on an ultrafleXtreme (Bruker, Germany) in positive, reflectron ion mode. The instrument is equipped with SmartBeam laser (355 nm), and the applied acceleration voltage was 8 kV in the positive ion mode. MS/MS spectra were obtained in the LIFT mode with the isolation of the monoisotopic peak. Obtained spectra were processed using FlexAnalysis (3. 4. 76. 0) and BioTools (3. 2. SR3). Identification searches were performed against NCBIprot database “Mammalia” (release 224,02/2018 with 207,040,555 sequences) and against a contaminant database. Following parameters were used: precursor ion mass tolerance ± 200 ppm, product ion mass ± 1. 0 Da, two missed trypsin cleavages and constant carbamidomethylation of Cys. Variable modifications such as N-acetylation, C-amidation, ammonia loss from N-terminal Cys, modification of N-terminal Gln to pyro-Glu, oxidation of Met, His or Trp and phosphorylation of Ser, Thr or Tyr were taken into account. Proteins were confidently identified by peptide mass fingerprint (PMF) and peptide sequencing if statistical scores were above respective threshold levels. Throughout the isolation procedure total protein concentration was estimated spectrophotometrically by use of the Eq (2) [32], γ[mgmL‐1]= (A228. 5nm–A234. 5nm) ×f×dilutionfactor (2) where Ehresmann' s factor" f" for equine IgG of 0. 2553 was used [33]. Appropriate dilution of each sample was independently prepared three times to obtain the mean value of the measured concentrations for further calculation of yield and purity. Size-exclusion chromatography (SEC), which was employed for monitoring of IgG/F (ab’) 2 purity in all purification steps, as well as for analysis of pepsin preparation, was performed on TSK-Gel G3000SWXL column (7. 8 × 300 mm) with 0. 1 M phosphate-sulphate running buffer, pH 6. 6, at a flow rate of 0. 5 mL min-1 on Waters HPLC system (Waters, USA). The effluent was monitored at 280 nm. For determination of the IgG/F (ab' ) 2 molecular weight, tyroglobulin (Mr 665,000), γ-globulin (Mr 150,000), ovalbumin (Mr 44,300) and ribonuclease A (Mr 13,700) were used as standards. Correction factor corresponding to deviation of molecular mass of analysed IgG, determined according to calibration curve, from its nominal molecular mass, was included in the calculation. ELISA for detection of specific antibodies in samples from HHP processing was performed by coating the microtiter plate with 100 μL / well of the venom coating solution (1 μL mL-1) in 50 mM carbonate buffer, pH 9. 6, and left overnight at RT. After blocking with 0. 5% (w/V) BSA in PBS with 0. 05% (V/V) Tween 20 at 37 °C for 2 h, the starting plasma and samples from each purification step were added in 2-fold serial dilutions in duplicates and left overnight at RT. In IgG ELISA affinity purified IgG (eIgG) of precisely determined protein concentration served as a standard. In F (ab’) 2 ELISA European viper venom antiserum (Zagreb antivenom, Institute of Immunology Inc.) was used as a standard. In the subsequent steps of ELISA, incubation with HRP-anti-horse F (ab׳) 2 IgG (25,000-fold diluted) at 37 °C for 2 h occurred, followed by the addition of OPD (0. 6 mg mL-1 solution) in citrate-phosphate buffer, pH 5. 0. After 30 min of incubation in the dark, the enzymatic reaction was stopped with 1 M H2SO4 and the absorbance at 492 nm was measured. Considering composition differences in subclass and/or venom-specific antibody distribution between each investigated sample and the standard, a recently developed principle for IgG or F (ab' ) 2 estimation that uses sample-specific correction was applied [33]. Namely, for IgG determination a highly pure IgG-based product (pure IgG sample in Fig 9), which was processed from the respective HHP and precisely quantified, served as internal, sample-specific reference. Analogously, for F (ab’) 2 quantification in process intermediates downstream of pepsin digestion step the purest F (ab’) 2 preparation of precisely determined concentration (ultrapure F (ab’) 2 in Fig 9) served as internal, sample-specific reference. Concentrations determined by ELISA assays were used for yield and purity calculations. IgG yield was calculated as: [ (γ (IgG) × dilution factor) / γ (IgG) in starting material] × 100%. Purity of each IgG intermediate was expressed as: (γ (IgG) / γ (protein) ) × 100%. F (ab' ) 2 yield was calculated as: [ (γ (F (ab' ) 2) × dilution factor) / (γ (IgG) in starting material × 0. 67) ] × 100%. Purity of each F (ab' ) 2 intermediate and final product was expressed as: (γ (F (ab' ) 2) / γ (protein) ) × 100%. Additionally, SEC monitoring for purity profiling throughout the manufacturing procedure was included also. The potential of HHP and pure IgG/F (ab' ) 2 preparation to neutralise the venom’s lethal toxicity was determined by the lethal toxicity neutralisation assay in mice, as previously described [34]. The lethal toxicity neutralisation potency (R) was expressed as the number of LD50 venom doses that can be neutralised by 1 mL of undiluted sample and calculated by the Eq (3), R= (Tv‐1) /ED50 (3) where Tv represents the number of LD50 venom doses inoculated per mouse. R-value was used as a measure of the protective efficacy of each sample. Specific activity (LD50 mg-1) was expressed as ratio of R-value and either active principle (IgG or F (ab' ) 2) or total protein concentration. Unless stated otherwise, the results of each analysis are expressed as the average of n measurements, with uncertainty of measurements expressed as 95% CI. Number of measurements for each analysis (n) is given.
Initially, heat-treated (defibrinogenated) HHP was fractionated by caprylic acid (1–9%, V/V). As became evident after centrifugation, concentrations higher than 3% negatively affected visual appearance of the supernatant, causing excessive turbidity and formation of a non-precipitable layer on top of the aqueous phase. Thus, only samples fractionated by lower concentrations were further analysed for IgG and total protein content. According to ELISA-based calculations, the investigated range of caprylic acid concentrations (1–3%) did not precipitate IgG molecules, leaving them completely in supernatant, while the lowest one significantly impaired their purity (Fig 1). At 2% caprylic acid, precipitation of almost all unwanted proteins occurred. Higher concentration did not exhibit any obvious beneficial effect. Caprylic acid at a volume ratio of 2% was identified to be the minimal quantity required for preservation of yield and acquisition of high purity so it was chosen as optimal for HHP fractionation. Based on ELISA results, 2% caprylic acid enabled the preparation of crude IgG sample almost without any losses and at > 80% purity (Table 1). SEC analysis of samples from two initial steps, heat-treatment and precipitation, confirmed significant reduction of the non-IgG protein content in supernatant as well (Fig 2A and 2B). SDS-PAGE profiles are shown in Fig 3A (lanes 1 or 2 and 4). The molecular mass of equine IgG, assessed by SEC, was 153. 5 ± 1. 5 kDa (n = 78). Commercial pepsin preparation involved in the manufacturing procedure had 7 times lower total protein concentration in comparison to the one derived from the weighted mass. In addition, when analysed by SDS-PAGE, notable contamination of the enzyme with autodigestion and/or manufacturing by-products was observed (Fig 3B). SEC profile corroborated the obtained results concerning composition of the enzyme preparation, revealing that only 48. 4 ± 0. 8% (n = 6) of the whole protein content actually corresponds to pepsin with a molecular weight of 35. 9 ± 0. 1 kDa (n = 6) (Fig 4A). The majority of contaminating proteins/peptides was approximately 10 kDa or less. As demonstrated, their complete removal could be achieved through diafiltration on a 50 kDa membrane (Fig 4B) which at the same time leads to the loss of 40% of pepsin content. Study in a batch mode on UNOsphere Q stationary phase for optimisation of the chromatographic separation of pepsin from F (ab’) 2 fragments revealed pH 5. 0 as the most convenient for achieving a good balance between its removal by adsorption to anion-exchange support and retention of the active principle in solution with minimal loss. So it was further used for the final polishing step. Namely, each of the investigated pH values (4. 0,5. 0 or 6. 0) resulted in good F (ab' ) 2 fragment yield of minimum 85% (Table 2). The presence of 0. 15 M NaCl in the binding buffer had a slightly positive impact on their recovery in the unbound fraction, at the same time unaffecting quantity of the pepsin retained on the support. Although the highest F (ab' ) 2 yield was achieved under conditions employing pH 4. 0, contaminating traces of pepsin were confirmed in the unbound fraction, as concluded from the presence of a' ' negatively' ' silver stained band at position corresponding to its molecular weight (Fig 7A) [35].
The production of immunotherapeutics has always been a struggle of finding balance between retaining the potency of the product and reducing the appearance of its side effect-inducing properties. From the standpoint of antivenom manufacturing, consistent quality, safety and clinical efficacy are usually ensured through removal of the immunogenic Fc part of the IgGs previously fractionated from other plasma proteins and purification of the F (ab' ) 2-based preparation from residual contaminants. Although deprived from innovative technological breakthroughs, our refining scheme (Fig 9) provides a finely tuned approach through which high yield and fulfillment of regulatory demands in the most straightforward way were achieved. Also, since the process efficiency has been supported with quantitative data, economic feasibility can be easily evaluated. The development of the processing platform was demonstrated on HHP pool raised against V. ammodytes venom (S2 Fig). The emphasis was put on the active principle handling by preserving it in solution throughout the manufacturing procedure. Unwanted precipitation of IgGs was avoided by employing caprylic acid-mediated fractionation as a method introduced by Steinbuch and Audran [9]. This method is generally considered to represent a mild treatment. We found that the lowest volume ratio of precipitating agent with the most beneficial impact on purification fold was 2% (Fig 1). Preferential use of caprylic acid in the range of 1. 5–3% has been described on a few other occasions, accompanied by the reports of boosting IgG purity to over 90% [18,19,36,37]. Higher concentrations are usually associated with excessive tubidity and slower filtration rates [18,36,38,39]. Fernandes et al. [38] noticed complete precipitation of albumin when 2% caprylic acid was employed. Our result was not in accordance with such finding since the same protein, although significantly depleted, proved as one of the most persistant contaminants in crude IgG sample, together with a low content of aggregates and < 13 kDa material, as detected by SEC. Since caprylic acid precipitation or pepsin digestion do not change IgG subclass distribution, ELISA with a sample-specific correction of results [33] was found suitable for precise quantification of active principle. It has been chosen over other methods, such as SEC where overlapping of peaks or influence of protein type on surface area due to varying absorption and/or column adsorption characteristics is highly probable, leading to inaccurate result interpretation [40]. For instance, the resolution of SEC does not allow detection of potential impurities such as IgA, IgE and ceruloplasmin, which overlap with major peaks corresponding to IgG and albumin, as already emphasised [41]. Densitometric analysis of CBB or silver stained protein bands in SDS-PAGE, another method of purity profiling, also exhibits major drawback since intensity of developed color highly depends on amino acid composition and usually has a limited dynamic range [42]. According to ELISA-based calculations, yield of crude IgG preparation was almost 90% in regards to the input material (Table 1). The majority of loss occurred during the heat treatment step, probably due to entrapment of portion of IgG molecules into the denatured fibrinogen network. The literature in general lacks supportive data concerning recovery. For instance, Rojas et al. [7] reported 60% yield of caprylic acid-fractionated IgGs that has been considered as a satisfactory outcome [13]. Optimal conditions for pepsin digestion of equine IgGs, established on highly pure preparation from protein A chromatography, proved inadequate when crude IgG sample from precipitation step was employed as substrate because in the acidic environment residual caprylic acid provoked aggregation (Fig 6). Therefore, diafiltration as an intermediate step was introduced, also contributing to purity increase (Table 1), which was comparable to that reported by other groups [19,37,41]. ELISA-based yield assessment was additionally supported by in vivo assay, revealing purification factor of about 2-fold (Table 3). SEC analysis showed only 1–2% of aggregates. This is in line with literature as antivenoms derived from the whole IgGs purified by caprylic acid fractionation usually display low degree of aggregation [8,12,43]. In addition, protective efficacy of IgG preparation against V. ammodytes venom was congruent to that of the respective plasma pool (Table 3), indicating preservation of IgG subclasses and invariance of venom-specific antibody content through manufacturing process. As such, the pure IgG sample, although firstly regarded only as input material for subsequent antivenom manufacturing, later was recognised as possible production exit point as well due to compliance with regulatory frameworks concerning neutralisation potency and physicochemical profile [1]. Efficient pepsin cleavage aims for total IgG fraction breakdown and circumvention of over-digestion. The reaction should progress to the degree of Fc part removal only. In our protocol, complete removal yet limited hydrolysis was dependent on recognising 0. 15 M NaCl as more appropriate for pepsin activity, adjusting enzyme to IgG ratio to 4: 300 (w/w), setting pH to 3. 2 and prolonging the incubation period to 1. 5 h. We considered the avoidance of any kind of burden for the manufacturing process by introducing purity-compromising reagents such as pepsin in unrationaly high amounts. Namely, even shorter reaction time can be used but apparently seeks for higher enzyme concentrations to achieve comparable recovery levels [26]. Following digestion, apart from F (ab' ) 2 fragments and by-products of enzymatic cleavage, a small amount of high molecular weight material near the exclusion limit (> 500,000 Da) was observed in SEC analysis (Fig 2D), but could not be seen by SDS-PAGE (Fig 3A, lane 6). This fraction might contain aggregated acidic low molecular weight fragments of Fc and/or other non-IgG fragments, as assumed by Jones and Landon [23] who noticed similar phenomenon following pepsin digestion of ovine serum. When diafiltration on 50 kDa membrane was employed for purity enhancement, basically only F (ab' ) 2 product was detected (Figs 2E and 3A). Since no evidence of high molecular weight material was observed, dissociation of aggregates due to buffer exchange and washing out of released protein segments is very likely. Physicochemical profile of the pure F (ab' ) 2 sample was equally good or better from that of some other final F (ab' ) 2 products generated by various methodologies from hyperimmune plasma or serum on laboratory scale [18,19,26,38,41]. A recovery approaching 80% (Table 1) was favorably comparable to that reported for pepsin digested-hyperimmune antirabies serum prior its subsequent refinement by caprylic acid fractionation and diafiltration [38]. As already noticed by Jones and Landon [25], diafiltration was only partially efficient at removing pepsin (Fig 4A and 4B). Therefore, a third and final purification step was introduced. Polishing was performed by means of anion-exchange chromatography at pH 5. 0 which allowed binding of residual acidic impurities, including the remaining pepsin content, and their segregation from F (ab' ) 2 fragments which passed through the column and remained in solution. The methodology has already been successfully demonstrated on digestion product of ovine serum-derived IgG fraction [23,25]. SEC profile indicated that completely pure and aggregate-free F (ab' ) 2-based preparation was achieved (Figs 2F and 3A). In order to get a deeper insight on its purity or contaminant profile, as additional insurance of the final product quality, 2D gel electrophoresis and MS analysis were performed. Among traces of impurities only transthyretin was identified (Fig 8, S1 Table). Other low-abundance protein spots did not contain sufficient material for successful MS analysis and their identification failed. Exceptionally high purity of the final product is creditable to supplementing action of diafiltration and anion-exchange chromatography. Namely, diafiltration removes whole fraction of contaminating proteins/peptides from the pepsin preparation, which lack capability of binding to CIM QA disk, while anion-exchange chromatography depletes the other half of the enzyme material, latter remaining in retentate post-diafiltrationally. Overall yield of around 75% or higher (Table 1) was in the range of that reported for ovine serum as input material for fractionation with assumption that between 30 and 32 g of IgG per L are commonly found in immunised animal [19,23]. ELISA-based calculation has been supported by the result of a lethal toxicity neutralisation assay in mice (Table 3). Functionality of the final product in terms of protective efficacy was comparable to that of the respective plasma pool and thus fully preserved. Thus, apart from quantity loss, reduction of neutralisation potency of F (ab' ) 2 fragments due to denaturation induced by acidic conditions during pepsin digestion step can be excluded also, meaning that a good balance between pH level and reaction time was achieved. On the contrary, under quite similar pH/time conditions some authors noticed a decrease in F (ab' ) 2 antigen-binding activity of around 35%, measured by competitive ELISA stated to be in close correlation with ED50 assay [44]. Others reported that performance of digestion at pH of 2. 8–3. 2 caused even 50% reduction of the plasma potency assessed in mice [45]. In addition, congruent protective efficacy of the final product and starting material points that no substantial IgG subclass loss and, consequently, redistribution of the venom-specific antibody content occurred. In conclusion, fractionation of the venom-specific plasma was efficiently performed on laboratory scale by sequence of optimised purification steps—precipitation of unwanted proteins by caprylic acid, removal of precipitating agent from IgG-enriched fraction, pepsin digestion, diafiltration of the obtained F (ab' ) 2 preparation and its final polishing by flow-through chromatography. During the whole process IgGs or F (ab' ) 2 fragments were kept in solution, ensuring quality and, therefore, safety of the final product. Manufacturing protocol has been performed independently several times on two plasma pools of slightly different protective efficacy. Also, two analysts were involved. Refining scheme resulted in the completely pure, aggregate- and pepsin-free active principle with overall yield advantageously comparable to others so far reported. Suitability for larger scale production, as well as estimation of its cost-effectivenes, should be determined through additional study, together with stability, pre-clinical and clinical efficacy of the final product prepared according to optimised procedure.
Animal plasma-derived antivenoms constitute the most important therapy against snakebite envenoming. Nowadays this critical treatment has been faced by severe shortage due to low sustainability of current productions, which mostly affects developing countries as those suffering from highest morbidity and mortality rates. Antivenoms' safety and efficacy in clinical setting are highly dependent on manufacturing procedure. Its design should be guided by the tendency to refine immunoglobulin G from residual plasma proteins in only a few easy, simple and efficient purification steps, providing antibody-based product of acceptable physicochemical features and good recovery of protective activity. Here, we developed a compact, feasible and economically viable refinement strategy for antivenom preparation which looks promising for large scale production as well. Process design was driven by the imperative of keeping IgGs or F (ab' ) 2 fragments constantly in solution in order to preserve stability of their conformations. In each of three main steps—caprylic acid precipitation for removal of contaminants, pepsin digestion of IgGs and chromatographic polishing of F (ab' ) 2 active principle, optimal performance conditions were defined. As a result, preparation of completely homogenous and aggregate-free final product with over 75% yield was achieved in the most straightforward way. Also, the novel platform has been supported with process efficiency data, so accurate estimation of the cost-effectiveness is enabled.
medicine and health sciences
enzyme-linked immunoassays
toxins
pathology and laboratory medicine
enzymes
enzymology
toxic agents
toxicology
optimization
mathematics
immunologic techniques
gel electrophoresis
pepsins
research and analysis methods
venoms
specimen preparation and treatment
staining
electrophoretic techniques
electrophoretic staining
proteins
immunoassays
chemistry
chemical precipitation
biochemistry
hydrolases
plasma proteins
biology and life sciences
chemical reactions
physical sciences
silver staining
Refinement strategy for antivenom preparation of high yield and quality